AP Biosciences, Inc. (TPEX:6945)
Taiwan · Delayed Price · Currency is TWD 95.80
+0.50 (0.52%)
Sep 8, 2026, 1:30 PM CST
AP Biosciences Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
9.29B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 32.25M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 6.99M | -130.57M | -94.92% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Adimmune | 1.37B |
| Savior Lifetec | 1.12B |
| PharmaEngine | 1.03B |
| TCM Biotech International | 701.63M |
| Tanvex BioPharma | 657.56M |
| Polaris Group | 67.95M |
| ACRO Biomedical | 52.76M |
| Lumosa Therapeutics | 34.37M |